Earnings Feed
Start Free
Akari Therapeutics Plc·4

Sep 18, 4:40 PM ET

Bazemore Robert B 4

4 · Akari Therapeutics Plc · Filed Sep 18, 2024

Insider Transaction Report

Form 4
Period: 2024-09-17
Akari Therapeutics PlcAKTX
Bazemore Robert B
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    2024-09-17+5,000,000→ 5,000,000 total
    Exercise: $0.00Exp: 2034-09-17→ Ordinary Shares, par value $0.0001 per share (5,000,000 underlying)
Footnotes (3)
  • [F1]The stock options have an exercise price of $0.001655 per ordinary share, par value $0.0001 per share ("Ordinary Share").
  • [F2]Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. The stock option vests and becomes exercisable ratably in three equal installments with the first installment vesting on the date of the first Annual General Meeting ("AGM") following the date of the grant, and with the second and third installments vesting, respectively, on the dates of the second and third AGM's following the date of the grant, subject to the non-employee director's continued service with the Issuer.
  • [F3]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.

Documents

2 files